PPMX-T002 is under clinical development by Perseus Proteomics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect PPMX-T002’s likelihood of approval (LoA) and phase transition for Triple-Negative Breast Cancer (TNBC) took place on 10 Oct 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their PPMX-T002 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

PPMX-T002 overview

PPMX-T002 (FF-21101) is under development for the treatment of solid tumors including pancreatic neuroendocrine tumor, ovarian cancer, liposarcoma, vaginal cancer, desmoplastic small round cell (DSRC) tumor  epithelial ovarian cancer, peritoneal cancer, fallopian tube carcinoma, metastatic biliary tract cancer, triple negative breast cancer (TNBC), head and neck squamous cell carcinoma (HNSCC), cholangiocarcinoma, pancreatic carcinoma and colorectal cancer. The drug is administered by injection. It is a radioimmunoconjugate consisting of a chimeric monoclonal antibody targeting human cadherin-3 (CDH3) and labeled, via the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), with the beta-emitting radioisotope yttrium Y 90.

It was also under development for the treatment of oral cavity (mouth) cancer, papillary tumor, maxillary sinusitis, oropharyngeal cancer, hypopharyngeal cancer,  non-small cell lung cancer, islet cell carcinoma and laryngeal cancer.

Perseus Proteomics overview

Perseus Proteomics (PPMX), a subsidiary of Fujifilm Holdings Corp, is a developer of antibody based therapeutics and diagnostics, research reagents and nuclear hormone receptor drugs. The company’s antibody products comprise nuclear receptor and epigenetics, among others. Its antibodies are used for diagnosis and offer treatment for diabetes, heart disease and cancer. PPMX’s antibodies are used in life science applications including drug discovery screening, and diagnostic imaging for radiation therapy, antibody-based cancer therapeutics and detection of cancer or metabolic disease biomarkers. The company also offers transcriptome database analysis and Elisa kits. PPMX is headquartered in Tokyo, Japan.

Quick View PPMX-T002 LOA Data

Report Segments
  • Innovator
Drug Name
  • PPMX-T002
Administration Pathway
  • Intravenous
  • Parenteral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.